ArticleAntibody therapeutics2026

A glycoengineered anti-ROR1 antibody, GE-zilovertamab, selectively enhances antibody-dependent cellular cytotoxicity against chronic lymphocytic leukemia.

Md Kamrul Hasan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.